中国科学院院士陈竺与法国科学家安妮·德尚、戴宇阁于本周二晚共同荣获2026年度邵逸夫生命科学与医学奖,颁奖地点为香港会展中心 1。该奖项旨在表彰三人在急性早幼粒细胞白血病(APL)分子机制阐释及协同靶向治疗方案开创方面的杰出贡献 1。相关疗法成功将APL从一种致死率极高的癌症转变为治愈率超过90%的疾病 1。在颁奖现场,陈竺表示:“本次奖金,全部捐出”,这笔资金将用于中国慢病防控事业 1。
回顾该领域的研究历程,早在1988年,王振义便在《血液》杂志上发表了关于全反式维甲酸临床应用的首篇论文;1991年,维甲酸受体被发现 1。陈竺曾师从王振义,并与妻子陈赛娟合作,二人曾在法国抗癌基金资助的十万法郎支持下购置仪器,并带回十二个大箱子的试剂回国开展研究 1。尽管拥有多种社会身份,陈竺表示他最看重的头衔依然是“中国科学院院士” 1。截至2026年,已有18位邵逸夫奖得主获得诺贝尔奖 1。
Academician of the Chinese Academy of Sciences Chen Zhu, along with French scientists Anne De Thé and Hugues de Thé, has been awarded the 2026 Shaw Prize in Life Science and Medicine 1. The honor recognizes their pioneering work on the molecular mechanisms of acute promyelocytic leukemia (APL) and the development of synergistic targeted therapies 1. This collaborative effort transformed APL from a cancer with extremely high mortality into a disease with a cure rate exceeding 90% 1. During the announcement on Tuesday evening at the Hong Kong Convention and Exhibition Centre, Chen declared that he would donate the entire prize money to support chronic disease prevention initiatives in China 1.
The awarding ceremony highlighted the long-standing scientific collaboration between Chen and his mentors. Chen studied under Wang Zhenyi, who published the first clinical application paper on all-trans retinoic acid in the journal Blood in 1988 1. In 1991, Wang discovered the retinoic acid receptor, laying crucial groundwork for future treatments 1. Chen also worked closely with his wife, Chen Saijuan, to advance these medical breakthroughs 1. To facilitate this research, a French anti-cancer fund provided 100,000 francs for instrument purchases, while Chen and his wife transported twelve large boxes of reagents back to China 1.
Chen emphasized that his most valued title remains "Academician of the Chinese Academy of Sciences" 1. The Shaw Prize continues to serve as a significant indicator of Nobel-level achievements; by 2026, eighteen Shaw Prize laureates have subsequently won Nobel Prizes 1.
评论
还没有评论,欢迎留下第一条。